Acid and Nonacid Reflux Monitoring

Gastroenterology Clinics of North America

Volumn 43, Issue 1, 2014, Pages 89-104

  Carlson, Dustin A ^a   Pandolfino, John E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Esophageal reflux monitoring; Gastroesophageal reflux disease; Impedance; Nonacid reflux; PH monitoring

Indexed keywords

ESOPHAGEAL REFLUX MONITORING; GASTROESOPHAGEAL REFLUX DISEASE; IMPEDANCE; NONACID REFLUX; PH MONITORING;

ELECTRIC IMPEDANCE; ESOPHAGEAL PH MONITORING; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 84895075949     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2013.11.003     Document Type: Review

References (73)

1. Vakil N., van Zanten S.V., Kahrilas P., et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101(8):1900-1920. [quiz: 1943].
2. Peery A.F., Dellon E.S., Lund J., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012, 143(5):1179-1187.e1-3.
3. Sifrim D., Castell D., Dent J., et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004, 53(7):1024-1031.
4. Kahrilas P.J., Shaheen N.J., Vaezi M.F. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135(4):1392-1413.
5. Jackson P.G., Gleiber M.A., Askari R., et al. Predictors of outcome in 100 consecutive laparoscopic antireflux procedures. Am J Surg 2001, 181(3):231-235.
6. Bytzer P., Jones R., Vakil N., et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012, 10(12):1360-1366.
7. Pandolfino J.E., Vela M.F. Esophageal-reflux monitoring. Gastrointest Endosc 2009, 69(4):917-930. 930.e1.
8. Hirano I., Richter J.E. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007, 102(3):668-685.
9. Jobe B.A., Richter J.E., Hoppo T., et al. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the esophageal diagnostic advisory panel. JAm Coll Surg 2013, 217(4):586-597.
10. Cremonini F., Wise J., Moayyedi P., et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005, 100(6):1226-1232.
11. Kahrilas P.J., Hughes N., Howden C.W. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011, 60(11):1473-1478.
12. Hewson E.G., Sinclair J.W., Dalton C.B., et al. Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med 1991, 90(5):576-583.
13. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the diagnosis and management ofgastroesophageal reflux disease. Am J Gastroenterol 2013, 108(3):308-328. [quiz: 329].
14. Vaezi M.F., Richter J.E. Duodenogastroesophageal reflux and methods to monitor nonacidic reflux. Am J Med 2001, 111(Suppl 8A):160S-168S.
15. Marshall R.E., Anggiansah A., Owen W.A., et al. The relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease. Gut 1997, 40(2):182-187.
16. Marshall R.E., Anggiansah A., Manifold D.K., et al. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut 1998, 43(5):603-606.
17. Netzer P., Gut A., Brundler R., et al. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther 2001, 15(9):1375-1384.
18. Aksglaede K., Funch-Jensen P., Thommesen P. Intra-esophageal pH probe movement during eating and talking. A videoradiographic study. Acta Radiol 2003, 44(2):131-135.
19. Fletcher J., Wirz A., Henry E., et al. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut 2004, 53(2):168-173.
20. Pandolfino J.E., Lee T.J., Schreiner M.A., et al. Comparison of esophageal acid exposure at 1 cm and 6 cm above the squamocolumnar junction using the Bravo pH monitoring system. Dis Esophagus 2006, 19(3):177-182.
21. Lacy B.E., O'Shana T., Hynes M., et al. Safety and tolerability of transoral Bravo capsule placement after transnasal manometry using a validated conversion factor. Am J Gastroenterol 2007, 102(1):24-32.
22. Wong W.M., Bautista J., Dekel R., et al. Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring-a randomized trial. Aliment Pharmacol Ther 2005, 21(2):155-163.
23. Marchese M., Spada C., Iacopini F., et al. Nonendoscopic transnasal placement of a wireless capsule for esophageal pH monitoring: feasibility, safety, and efficacy of a manometry-guided procedure. Endoscopy 2006, 38(8):813-818.
24. Bell N.J., Burget D., Howden C.W., et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992, 51(Suppl 1):59-67.
25. Hoppo T., Komatsu Y., Jobe B.A. Antireflux surgery in patients with chronic cough and abnormal proximal exposure as measured by hypopharyngeal multichannel intraluminal impedance. JAMA Surg 2013, 148(7):608-615.
26. Komatsu Y., Hoppo T., Jobe B.A. Proximal reflux as a cause of adult-onset asthma: the case for hypopharyngeal impedance testing to improve the sensitivity of diagnosis. JAMA Surg 2013, 148(1):50-58.
27. Pandolfino J.E., Richter J.E., Ours T., et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003, 98(4):740-749.
28. Andrews C.N., Sadowski D.C., Lazarescu A., et al. Unsedated peroral wireless pH capsule placement vs. standard pH testing: a randomized study and cost analysis. BMC Gastroenterol 2012, 12:58.
29. Ahlawat S.K., Novak D.J., Williams D.C., et al. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system. JClin Gastroenterol 2006, 40(1):20-24.
30. Wenner J., Johnsson F., Johansson J., et al. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol 2007, 102(2):239-245.
31. Pandolfino J.E., Bianchi L.K., Lee T.J., et al. Esophagogastric junction morphology predicts susceptibility to exercise-induced reflux. Am J Gastroenterol 2004, 99(8):1430-1436.
32. Arora A.S., Murray J.A. Streamlining 24-hour pH study for GERD: use of a 3-hour postprandial test. Dig Dis Sci 2003, 48(1):10-15.
33. Fink S.M., McCallum R.W. The role of prolonged esophageal pH monitoring in the diagnosis of gastroesophageal reflux. JAMA 1984, 252(9):1160-1164.
34. Grande L., Pujol A., Ros E., et al. Intraesophageal pH monitoring after breakfast+ lunch in gastroesophageal reflux. JClin Gastroenterol 1988, 10(4):373-376.
35. Dhiman R.K., Saraswat V.A., Mishra A., et al. Inclusion of supine period in short-duration pH monitoring is essential in diagnosis of gastroesophageal reflux disease. Dig Dis Sci 1996, 41(4):764-772.
36. Hirano I., Zhang Q., Pandolfino J.E., et al. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005, 3(11):1083-1088.
37. Scarpulla G., Camilleri S., Galante P., et al. The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4-day wireless pH studies. Am J Gastroenterol 2007, 102(12):2642-2647.
38. Calabrese C., Liguori G., Gabusi V., et al. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. Aliment Pharmacol Ther 2008, 28(2):250-255.
39. Garrean C.P., Zhang Q., Gonsalves N., et al. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy. Am J Gastroenterol 2008, 103(7):1631-1637.
40. Hemmink G.J., Weusten B.L., Oors J., et al. Ambulatory oesophageal pH monitoring: a comparison between antimony, ISFET, and glass pH electrodes. Eur J Gastroenterol Hepatol 2010, 22(5):572-577.
41. Heard R., Castell J., Castell D.O., et al. Characterization of patients with low baseline impedance on multichannel intraluminal impedance-pH reflux testing. JClin Gastroenterol 2012, 46(7):e55-e57.
42. Roman S., Mion F., Zerbib F., et al. Wireless pH capsule-yield in clinical practice. Endoscopy 2012, 44(3):270-276.
43. Mainie I., Tutuian R., Agrawal A., et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006, 93(12):1483-1487.
44. Vela M.F., Tutuian R., Katz P.O., et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003, 17(2):243-251.
45. Mainie I., Tutuian R., Shay S., et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006, 55(10):1398-1402.
46. Zerbib F., Roman S., Ropert A., et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006, 101(9):1956-1963.
47. Hemmink G.J., Bredenoord A.J., Weusten B.L., et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?. Am J Gastroenterol 2008, 103(10):2446-2453.
48. Savarino E., Zentilin P., Tutuian R., et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008, 103(11):2685-2693.
49. Bredenoord A.J., Weusten B.L., Timmer R., et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol 2006, 101(3):453-459.
50. Karamanolis G., Kotsalidis G., Triantafyllou K., et al. Yield of combined impedance-pH monitoring for refractory reflux symptoms in clinical practice. JNeurogastroenterol Motil 2011, 17(2):158-163.
51. Cao H., Rao S., Tang S.J., et al. Batteryless implantable dual-sensor capsule for esophageal reflux monitoring. Gastrointest Endosc 2013, 77(4):649-653.
52. Tamhankar A.P., Peters J.H., Portale G., et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. JGastrointest Surg 2004, 8(7):890-897. [discussion: 897-8].
53. Vela M.F., Camacho-Lobato L., Srinivasan R., et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001, 120(7):1599-1606.
54. Blonski W., Vela M.F., Castell D.O. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy. JClin Gastroenterol 2009, 43(9):816-820.
55. Charbel S., Khandwala F., Vaezi M.F. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005, 100(2):283-289.
56. Pritchett J.M., Aslam M., Slaughter J.C., et al. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009, 7(7):743-748.
57. Lodrup A.B., Reimer C., Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol 2013, 48(5):515-522.
58. Johnson L.F., DeMeester T.R. Development of the 24-hour intraesophageal pH monitoring composite scoring system. JClin Gastroenterol 1986, 8(Suppl 1):52-58.
59. Kahrilas P.J., Quigley E.M. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996, 110(6):1982-1996.
60. Schindlbeck N.E., Heinrich C., Konig A., et al. Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastroesophageal reflux disease. Gastroenterology 1987, 93(1):85-90.
61. Roman S., Bruley des Varannes S., Pouderoux P., et al. Ambulatory 24-h oesophageal impedance-pH recordings: reliability of automatic analysis for gastro-oesophageal reflux assessment. Neurogastroenterol Motil 2006, 18(11):978-986.
62. Johnson L.F., Demeester T.R. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974, 62(4):325-332.
63. Ayazi S., Lipham J.C., Portale G., et al. Bravo catheter-free pH monitoring: normal values, concordance, optimal diagnostic thresholds, and accuracy. Clin Gastroenterol Hepatol 2009, 7(1):60-67.
64. Wenner J., Johnsson F., Johansson J., et al. Wireless oesophageal pH monitoring: feasibility, safety and normal values in healthy subjects. Scand J Gastroenterol 2005, 40(7):768-774.
65. Shay S., Tutuian R., Sifrim D., et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004, 99(6):1037-1043.
66. Zerbib F., des Varannes S.B., Roman S., et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005, 22(10):1011-1021.
67. Zerbib F., Roman S., Bruley Des Varannes S., et al. Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clin Gastroenterol Hepatol 2013, 11(4):366-372.
68. Singh S., Richter J.E., Bradley L.A., et al. The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci 1993, 38(8):1402-1408.
69. Breumelhof R., Smout A.J. The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol 1991, 86(2):160-164.
70. Weusten B.L., Roelofs J.M., Akkermans L.M., et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994, 107(6):1741-1745.
71. Smith J.A., Decalmer S., Kelsall A., et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology 2010, 139(3):754-762.
72. Watson R.G., Tham T.C., Johnston B.T., et al. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux-the "sensitive oesophagus". Gut 1997, 40(5):587-590.
73. Taghavi S.A., Ghasedi M., Saberi-Firoozi M., et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005, 54(8):1067-1071.